Acadia Pharmaceuticals vs BridgeBio Pharma
ACAD and BBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and BBIO compare
BridgeBio Pharma is the larger company, worth 4.9 times as much as Acadia Pharmaceuticals ($15.2B against $3.1B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 14.8% for Acadia Pharmaceuticals).
Acadia Pharmaceuticals scores higher on the StockData Score (18 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | BBIO |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $15.2B |
| Share price | $18.14 | $78.17 |
| Change, 1 year | −23.5% | 17.4% |
| Change, 5 years | −5.3% | 83.3% |
| Beta (5Y) | 0.77 | 1.11 |
| Employees | 798 | 834 |
| StockData Score | ||
| Total score | 18 (better) | 3 |
| Valuation score | 5 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.6× | – |
| P/S | 2.6× (better) | 16.1× |
| P/B | 2.3× | – |
| EV/EBITDA | 17.6× | – |
| P/FCF | 38.1× | – |
| FCF yield | 2.6% (better) | −2.4% |
| Fair value | $31.57 | – |
| Margin of safety | 42.5% | – |
| Growth | ||
| Revenue growth (TTM) | 14.8% | 167% (better) |
| Revenue growth, 5Y average | 19.4% | 127% (better) |
| Net income growth (TTM) | 38.7% | – |
| EPS growth (TTM) | 35.5% | – |
| Profitability | ||
| Gross margin | 90.5% | 94.3% (better) |
| Operating margin | 10.2% (better) | −38.5% |
| Net margin | 30.1% | – |
| FCF margin | 6.8% (better) | −39.1% |
| Return on equity | 31.4% | – |
| Return on invested capital | 50.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −7.1× |
| Current ratio | 3.82 (better) | 2.09 |
| Altman Z-score | 4.79 (better) | 0.15 |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Buyback yield | −1.6% | 1.7% (better) |
| Shareholder yield | −1.6% | 1.7% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 99.4% |
| Held by insiders | 27.8% | 35.6% |
| Insider net buying, 12 months | −$2.5M (better) | −$84.8M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.7% | 16.6% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.